Immediate Impact
1 from Science/Nature 55 standout
Citing Papers
Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation
2025 Standout
Cancer therapy with antibodies
2024 Standout
Works of Ashraf Yassen being referenced
First evaluation of the safety, pharmacokinetics, and pharmacodynamics of BAY 2433334, a small molecule targeting coagulation factor XIa
2021
BAY 1213790, a fully human IgG1 antibody targeting coagulation factor XIa: First evaluation of safety, pharmacodynamics, and pharmacokinetics
2019
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| Ashraf Yassen | 243 | 434 | 168 | 611 | 436 | 27 | 1.6k | |
| Raymonda Romberg | 300 | 645 | 161 | 528 | 817 | 23 | 1.9k | |
| Babette Kögel | 382 | 676 | 267 | 255 | 352 | 30 | 1.3k | |
| David Wesche | 387 | 408 | 39 | 595 | 163 | 57 | 2.1k | |
| Rolf Terlinden | 101 | 462 | 385 | 207 | 403 | 33 | 1.2k | |
| Andrew Moore | 133 | 499 | 62 | 462 | 825 | 28 | 1.9k | |
| Tess Cramond | 220 | 510 | 46 | 143 | 562 | 44 | 1.4k | |
| Abraham Sunshine | 90 | 505 | 140 | 238 | 551 | 71 | 1.9k | |
| J. David Clark | 192 | 464 | 27 | 308 | 539 | 28 | 1.2k | |
| Teijo I. Saari | 147 | 248 | 77 | 210 | 894 | 61 | 2.0k | |
| Ulrich Jahnel | 373 | 668 | 163 | 211 | 354 | 28 | 1.3k |
All Works
Login with ORCID to disown or claim papers
Loading papers...